Emcure Pharma IPO
GMP, Subscription, Price, Dates & Financial Details
Incorporated in 1981, Emcure Pharmaceuticals Limited is a prominent Indian pharmaceutical company that develops, manufactures, and globally markets a diverse range of pharmaceutical products across several major therapeutic areas. As of September 2023, Emcure ranks 13th in domestic sales among…
Open Date
Wed, 03 Jul 2024
Close Date
Fri, 05 Jul 2024
Price Band
₹ 960 – 1008
Lot Size
14
Issue Size
₹ 1,952.03 Cr
Minimum Investment
₹ 14,112 (14 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Emcure Pharma IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹1,952.03 Crore, comprising a fresh issue of 79.37 Lakh equity shares aggregating to ₹800.00 Crore and an offer for sale (OFS) of 1.14 Crore equity shares aggregating to ₹1,152.03 Crore by the existing shareholders.
The Emcure Pharma IPO remained open for subscription from July 03, 2024, to July 05, 2024. The basis of allotment was finalized on July 08, 2024, and the company's shares were listed on the NSE and BSE on July 10, 2024.
The company had fixed the price band at ₹960 to ₹1008 per share, with a lot size of 14 shares. Retail investors were required to make a minimum investment of ₹14,112 (based on the upper price band) to apply for one lot.
The IPO also included a reservation of 108,900 equity shares for eligible employees, who received a discount of ₹90 per share.
MUFG Intime India Private Limited served as the registrar to the issue. Axis Capital Limited, J.P. Morgan India Private Limited, Kotak Mahindra Capital Company Limited, and Jefferies India Private Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Emcure Pharmaceuticals Limited is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Emcure Pharma IPO Timeline (Tentative)
- IPO Open Date
- Wed, 03 Jul 24
- IPO Close Date
- Fri, 05 Jul 24
- Basis of Allotment
- Mon, 08 Jul 24
- Initiation of Refunds
- Tue, 09 Jul 24
- Credit of Shares to Demat
- Tue, 09 Jul 24
- Listing Date
- Wed, 10 Jul 24 — NSE & BSE
Open Date
03 July 2024
Close Date
05 July 2024
Basis Of Allotment
08 July 2024
Listing Date
10 July 2024
IPO Subscription
Check Live Subscription →The Emcure Pharma IPO has received bids for 92,99,97,390 shares against 1,37,03,538 shares offered, resulting in an overall subscription of 67.87x. the NII category is subscribed 48.32x, Retail Investors 7.21x, Employees 8.81x, and QIBs 195.83x. Within the NII category, BNII is subscribed 53.79x, while SNII is subscribed 37.39x.
QIB
195.83x
NII
48.32x
RII
7.21x
EMP
8.81x
BNII
53.79x
SNII
37.39x
Total
67.87x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 67,43,160 shares, representing 34.61% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 38,53,234 shares (19.78%), while Non-Institutional Investors (NIIs) receive 28,89,926 shares (14.83%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Anchor Investors | 5,779,850 | 29.67% |
| Qualified Institutions | 3,853,234 | 19.78% |
| Non-Institutional | 2,889,926 | 14.83% |
| BNII | 1,926,618 | 9.89% |
| SNII | 963,309 | 4.94% |
| Retail Investors | 6,743,160 | 34.61% |
| Employees | 108,900 | 0.56% |
| Total | 19,483,388 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Mar 24 | 31 Mar 23 | 31 Mar 22 |
|---|---|---|---|
| Assets | 7806.16 | 6672.53 | 6063.47 |
| Revenue | 6715.24 | 6031.72 | 5918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| Net Worth | 2952.28 | 2501.13 | 1987.55 |
| Reserve & Surplus | 2722.4 | 2293.77 | 1791.03 |
| Total Borrowings | 2091.94 | 2202.42 | 2102.19 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Emcure Pharmaceuticals Limited KPI Information
| Particular | KPI Information |
|---|---|
| ROE % | 16.9 |
| ROCE % | 19.37 |
| Debt / Equity | 0.67 |
| RoNW % | 16.87 |
| PbW | 6.18 |
Peers Comparison
No Peer Comparision Available
About Emcure Pharmaceuticals Limited
Incorporated in 1981, Emcure Pharmaceuticals Limited is a prominent Indian pharmaceutical company that develops, manufactures, and globally markets a diverse range of pharmaceutical products across several major therapeutic areas.
As of September 2023, Emcure ranks 13th in domestic sales among Indian pharmaceutical companies and holds the 4th largest market share in its covered markets. The company has led the gynaecology and HIV antiviral therapeutic areas for the same period.
In the first half of FY 2023, sales in India accounted for 50.84% of Emcure's total revenue, while for the entire FY 2023, this figure was 53.16%. Between September 2019 and September 2023, Emcure’s domestic sales grew at a CAGR of 10.80%, surpassing the overall growth of the Indian pharmaceutical market.
Emcure employs 552 scientists and operates five research facilities in India, having filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. The company boasts 201 granted patents, 33 pending applications, and 102 drug master files.
The company's 13 manufacturing facilities in India produce a variety of pharmaceutical and biopharmaceutical products. Its marketing and distribution network in India is supported by over 5,000 field personnel and stockists, served by 37 carry-and-forward agents, ensuring a robust interaction with healthcare providers nationwide.
Peer Details
The companies considered by Emcure Pharmaceuticals as its peers include:
- Dr. Reddy's Laboratories Limited
- Cipla Limited
- Alkem Laboratories Limited
- Torrent Pharmaceuticals Limited
- Mankind Pharma Limited
- Abbott India Limited
- J. B. Chemicals & Pharmaceuticals Limited
Emcure Pharma IPO Promoters
- Satish Mehta
- Sunil Mehta
Promoters Holding
Holding Pre Issue
98.90%
Holding Post Issue
78.24%
Emcure Pharma IPO Objective
The company plans to allocate the net proceeds from the issuance to the following purposes:
- Repayment and/or prepayment of certain outstanding borrowings.
- General corporate purposes.
Emcure Pharmaceuticals Limited Address / Contact Details
Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune -411 057
Phone: +91 20 3507 0033
Email: investors@emcure.co.in
Website: https://www.emcure.com
IPO Snapshot
Emcure Pharma IPO Lot Size
The Emcure Pharma IPO has a lot size of 14 shares. Retail investors require a minimum investment of ₹14,112 by applying for 1 lot (14 shares). The maximum application allowed for the retail category is 14 lots (196 shares), requiring an investment of ₹1,97,568.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 14 | 14,112.00 |
| Retail (Max) | 14 | 196 | 197,568.00 |
| S-HNI (Min) | 15 | 210 | 211,680.00 |
| S-HNI (Max) | 70 | 980 | 987,840.00 |
| B-HNI (Min) | 71 | 994 | 1,001,952.00 |
Issue Reservation
- Anchor Investors — 29.67%
- QIB — 19.78%
- NII — 14.83%
- RII — 34.61%
- EMP — 0.56%
Book Running Lead Managers
- Axis Capital Limited
- J.P. Morgan India Private Limited
- Kotak Mahindra Capital Company Limited
- Jefferies India Private Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Emcure Pharma IPO?
Emcure Pharma IPO is a Book-building IPO with a total issue size of ₹1952.03 crore. The Emcure Pharma IPO price band is ₹960 to 1008 per share. The Emcure Pharma IPO subscription opens on Wed, Jul 3, 2024, and closes on Fri, Jul 5, 2024. The Emcure Pharma IPO will be listed on the BSE,NSE. MUFG Intime India Private Limited is the registrar for the Emcure Pharma IPO.
When will the Emcure Pharma IPO open for subscription?
The Emcure Pharma IPO opens on Wed, Jul 3, 2024 and closes on Fri, Jul 5, 2024
What is Emcure Pharma IPO Price Band?
Emcure Pharma IPO Price Band is ₹960 to 1008 per share.
What is Emcure Pharma IPO Lot Size?
Emcure Pharma IPO lot size is 14 shares, Retail investors need a minimum investment of ₹14112 based on the upper price band
What is the minimum investment for Emcure Pharma IPO?
The minimum investment for Emcure Pharma IPO is ₹14112, based on one lot of 14 shares at the upper price band of ₹1008 per share.
How to apply for Emcure Pharma IPO?
Investors can apply for the Emcure Pharma IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Jul 5, 2024. The application amount remains blocked until the Emcure Pharma IPO allotment is finalized.
What is Emcure Pharma IPO Issue Size?
Emcure Pharma IPO issue size is ₹1952.03 crores.
What is the Emcure Pharma IPO Allotment Date?
Emcure Pharma IPO allotment date is Mon, Jul 8, 2024.
Who is the Emcure Pharma IPO Registrar?
The registrar for Emcure Pharma IPO is MUFG Intime India Private Limited. Investors can go to MUFG Intime India Private Limited website to check Emcure Pharma IPO allotment status, refund processing, and other IPO-related information.
What is the Emcure Pharma IPO GMP?
The Emcure Pharma IPO GMP (Grey Market Premium) is ₹300 as of Wed, Jul 10, 2024. Based on the upper price band of ₹1008 per share, the estimated Emcure Pharma IPO listing price is ₹1308, indicating a potential listing gain of approximately 29.76% over the issue price.
Who is the Emcure Pharma IPO Lead Manager?
The book-running lead managers (BRLMs) for the Emcure Pharma IPO are Axis Capital Limited, J.P. Morgan India Private Limited, Kotak Mahindra Capital Company Limited, and Jefferies India Private Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Emcure Pharma IPO Red Herring Prospectus (RHP).